CN117462430A - 抗氧化组合物及其应用 - Google Patents
抗氧化组合物及其应用 Download PDFInfo
- Publication number
- CN117462430A CN117462430A CN202311532988.1A CN202311532988A CN117462430A CN 117462430 A CN117462430 A CN 117462430A CN 202311532988 A CN202311532988 A CN 202311532988A CN 117462430 A CN117462430 A CN 117462430A
- Authority
- CN
- China
- Prior art keywords
- composition
- hyaluronic acid
- lysine
- skin
- ergothioneine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000003078 antioxidant effect Effects 0.000 title claims description 20
- 239000003963 antioxidant agent Substances 0.000 title claims description 17
- 239000004472 Lysine Substances 0.000 claims abstract description 30
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 29
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 25
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 14
- 229940014041 hyaluronate Drugs 0.000 claims abstract description 12
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims abstract description 11
- 229940101267 panthenol Drugs 0.000 claims abstract description 6
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 6
- 239000011619 pantothenol Substances 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 4
- 230000002335 preservative effect Effects 0.000 claims abstract description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 28
- 229960003160 hyaluronic acid Drugs 0.000 claims description 28
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 25
- LWIGVRDDANOFTD-UHFFFAOYSA-N hydroxy(dimethyl)silane Chemical compound C[SiH](C)O LWIGVRDDANOFTD-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 abstract description 12
- -1 hyaluronate dimethyl silanol compound Chemical class 0.000 abstract description 9
- 230000003020 moisturizing effect Effects 0.000 abstract description 8
- 238000007254 oxidation reaction Methods 0.000 abstract description 8
- 206010051246 Photodermatosis Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000008845 photoaging Effects 0.000 abstract description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 24
- 235000018977 lysine Nutrition 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000000499 gel Substances 0.000 description 10
- 235000004866 D-panthenol Nutrition 0.000 description 7
- 239000011703 D-panthenol Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 229960003949 dexpanthenol Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000019766 L-Lysine Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 229940043267 rhodamine b Drugs 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SNPLKNRPJHDVJA-SSDOTTSWSA-N (2s)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide Chemical compound OCC(C)(C)[C@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-SSDOTTSWSA-N 0.000 description 1
- PIPJRNHXQAUIFQ-YFKPBYRVSA-N (2s)-3-(1h-imidazol-5-yl)-2-(sulfanylamino)propanoic acid Chemical group OC(=O)[C@@H](NS)CC1=CNC=N1 PIPJRNHXQAUIFQ-YFKPBYRVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- SERHXTVXHNVDKA-BYPYZUCNSA-N (R)-pantolactone Chemical compound CC1(C)COC(=O)[C@@H]1O SERHXTVXHNVDKA-BYPYZUCNSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- KMTDMTZBNYGUNX-UHFFFAOYSA-N 4-methylbenzyl alcohol Chemical compound CC1=CC=C(CO)C=C1 KMTDMTZBNYGUNX-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DCAADTQUFYNVHS-UHFFFAOYSA-N [SiH3]O.[Na] Chemical compound [SiH3]O.[Na] DCAADTQUFYNVHS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LONLGEZTBVAKJF-UHFFFAOYSA-N undecane-1,2,3-triol Chemical compound CCCCCCCCC(O)C(O)CO LONLGEZTBVAKJF-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明提供一种用于皮肤抗氧化的组合物，属于化妆品技术领域。本发明组合物的特征在于含有比例为100~200:1的透明质酸赖氨酸和麦角硫因，还可含有透明质酸二甲基硅烷醇复合物和/或泛醇以及化妆品常用防腐剂。本发明组合物用于制备皮肤护理产品具有显著的保湿和抗光老化作用。
Description
技术领域
本发明属于化妆品技术领域，涉及一种包含透明质酸赖氨酸和麦角硫因的皮肤护理组合物及其在化妆品中的应用。
背景技术
透明质酸（hyaluronic acid，HA）是由( 1-β-4 )D-葡萄糖醛酸和( 1-β- 3 )N-乙酰基-D-氨基葡萄糖双糖单位重复连接组成的链状聚阴离子黏多糖，它是构成皮肤细胞外基质的主要成分之一，由于具有显著的润滑、保湿效果，被广泛应用于化妆品中。透明质酸赖氨酸（Lysine hyaluronate，LH）是透明质酸和L-赖氨酸以离子键结合的有机盐化合物，由于HA结合了具有保湿、抗氧化和抗过敏作用的赖氨酸，因此除了具有良好的保湿作用外，还具有一定的抗氧化作用，应用于皮肤护理产品具有一定的抗衰、美白功效。LH在化妆品领域已应用十余年，由于其抗氧化作用较弱，在护肤品中多作为保湿剂使用。
麦角硫因（ergothioneine，EGT）是一种天然含硫氨基酸，1909年由法国药剂师Charles Tanret首次从麦角真菌中分离，随后也被发现存在于灵芝、松茸等菌菇中。外源性麦角硫因可以清除活性氧和氮以保护细胞免受氧化凋亡损伤，是一种高效抗氧化剂。由于EGT可以进入细胞线粒体中，发挥超过虾青素6倍的抗氧化功效，是一种理想的抗衰成分。应用于皮肤护理产品具有美白、防辐射、抗炎等功效。EGT可以抑制脂质过氧化损伤、清除羟自由基（·OH）、超氧化物和单线态氧（1O2）等多种活性氧（ROS）物质，是优异的皮肤光敏保护剂[参考文献：Markova N G , Karaman-Jurukovska N , Dong K K , et al. Skin cellsand tissue are capable of using L-ergothioneine as an integral component oftheir antioxidant defense system. Free Radic Biol Med, 2009, 46(8):1168-1176.]。机体的衰老最直接的表现就是皮肤衰老，除自然衰老的内部因素外，引起皮肤衰老的因素还来自于自然环境、外伤和接触某些化学物质等外界因素，其中最为常见的是日晒，即光老化。阳光中的紫外辐射照射到人体表皮细胞后可以产生1O2、·OH等有害物质，诱发DNA、蛋白质和细胞组织的损伤，导致皮肤的衰老和损伤。通过紫外线照射光敏剂罗丹明B（RhB）的溶液诱发包括1O2在内的自由基体系（UV-RhB体系），模拟紫外线照射人体皮肤产生活性氧导致的皮肤光老化模型，对EGT的抗氧化性能进行研究，结果表明，0.75mg/ml的EGT抗氧化性能与1mg/ml的维生素C相当，二者均有良好量效关系[孙赫,王丽丽,康传利等。麦角硫因抑制紫外辐射诱发自由基的试验研究，食品与药品，2023年第6期 ]。
EGT作为功效显著的天然抗氧化剂之一，被众多日化企业用于皮肤护理产品，市场需求量日益增加，但由于该成分无论采用生物提取、化学合成或生物合成等生产方式，均由于收率低，生产成本高、工艺复杂等因素，导致其原料价格居高不下，每公斤维持在几十万元不等，限制了它的使用。
本发明将EGT与LHA组合，采用较低的EGT使用量，提高LHA的抗氧化作用，本发明组合物用于制备抗衰美白功效的化妆品，保证效果的同时，降低产品生产成本。
发明内容
本发明的目的是提供一种包含透明质酸赖氨酸和麦角硫因的皮肤抗氧化组合物，以及所述组合物在皮肤护理化妆品领域的应用。
本发明所采用的技术方案为：
一种用于皮肤抗氧化的组合物，其特征是，至少包含透明质酸赖氨酸和麦角硫因两种成分。其中，透明质酸赖氨酸和麦角硫因按重量比为100 ~ 200:1，优选透明质酸赖氨酸和麦角硫因按重量比为120 ~ 150:1。
所述透明质酸赖氨酸（Lysine hyaluronate，LHA）为透明质酸与L-赖氨酸通过离子键结合的有机盐，其中每个构成透明质酸的二糖单元分子与L-赖氨酸结合的数目为0.4~1个，即LHA中L-赖氨酸的含量范围在10~30%（g/g）,优选L-赖氨酸的含量范围在13~19%（g/g）。
所述麦角硫因（ergothioneine，EGT）又名2- 硫代咪唑氨基酸，化学名为巯基组氨酸三甲基内盐，可以是从食用菌的子实体、猪血、动物组织、麦角和谷物中提取得到，也可以是通过化学合成方法获得，也可以通过生物发酵合成法获得，例如采用真菌菌丝体深层发酵技术生物合成提取纯化制备获得。
上述透明质酸赖氨酸的平均分子量范围在7kDa ~ 1000kDa，优选平均分子量范围在10KDa ~600kDa，更优选平均分子量范围在100kDa ~ 300kDa。
本发明皮肤抗氧化组合物，其特征是，还含有透明质酸二甲基硅烷醇复合物和/或泛醇。其中，透明质酸二甲基硅烷醇复合物可以是二甲基硅烷一醇与透明质酸的复合物，也可以是二甲基硅烷二醇与透明质酸的复合物，或者是二者的混合物。其获得可以采用已公开的制备方法，如将透明质酸溶液和硅烷醇钠溶液混合反应后用阳离子交换树脂调整pH获得复合物水溶液（FR2561915），按比例将硅烷醇水溶液和透明质酸水溶液混合（EP0289366），有机硅化合物与透明质酸在水和乙醇溶液中反应结合后蒸除溶剂（EP0867445），也可以采用氯硅烷与混悬在有机溶液中的透明质酸反应后经沉淀获得固体复合物（CN103450368）。其中，泛醇选自DL-泛醇，D-泛醇和/或L-泛醇，优选D-泛醇。D-泛醇又称为右旋泛醇、维生素原B5，化学名称为(R)-(+)-2,4-二羟基-N-(3-羟基丙基)-3,3-二甲基丁酰胺。D-泛醇可以来源于化学合成，也可以来源于微生物发酵提取，包括通过微生物酶法或化学法获得的D-泛解内脂与3-氨基丙醇反应获得的D-泛醇。
本发明皮肤抗氧化组合物，其特征是，透明质酸二甲基硅烷醇复合物的含量范围在0.05~20%，优选0.1~10%，更优选0.5~5%。
本发明皮肤抗氧化组合物，其特征是，泛醇的含量范围在0.05~5%，优选0.1~20%，优选0.5~10%，更优选1~5%。
本发明皮肤抗氧化组合物，可以制备不含防腐剂的次抛产品，也可以制备含有防腐剂的多剂量包装产品，后者通常含有化妆品常用的防腐剂，选自对羟基苯甲酸甲酯、对羟基苯甲酸丙酯、对甲基苄基醇、1,2-丙二醇、1,2-己二醇、1,2-戊二醇、对羟基苯乙酮、 3-[2-(乙基己基)氧]-1,2-丙二醇、1,2-辛二醇、丁二醇、苯乙醇、辛甘醇和苯氧乙醇其中的一种或两种以上的混合物。
本发明皮肤抗氧化组合物，其特征是，以凝胶和/或溶液的形式体现。即产品形式可以是凝胶，也可以是溶液，也可以是凝胶和溶液的混合物。组合物中透明质酸赖氨酸平均分子量较低和/或含量较小时，产品可呈现溶液状态；组合物中透明质酸赖氨酸的平均分子量较高和/或含量较大时，产品可呈现凝胶状态。
本发明抗氧化组合物可用于制备皮肤使用的保湿、抗衰和美白的化妆品。
本发明抗氧化组合物可直接用于面部和身体皮肤表面，也可以将本发明组合物用纯化水稀释、或加入化妆品常用的成分，配制成为溶液、凝胶、膏、霜或乳液等多种形式。例如爽肤水、面霜、面膜、防晒霜、晒后修复凝胶、身体乳和保湿喷雾等，用于体表和面部的皮肤护理。
本发明组抗氧化合物应用于体表皮肤可以起到预防光老化、减少皱纹和色斑形成等作用。
具体实施方式
以下实施例是为了更好地说明本发明，不是限制本发明。
实施例1 每100g抗氧化组合物中的成分和含量（g）如下表。
表1 不同配方抗氧化组合物的成分和含量（%，g/g）
按上述组合物配方，采用不同平均分子量的透明质酸赖氨酸配制以下组合物可以获得溶液状态或凝胶状态的产品。
表2 不同配方组合物的状态
上述组合物可直接用于面部和身体皮肤表面，也可以用纯化水稀释、或加入化妆品常用的成分，配制成为溶液、凝胶、膏、霜或乳液等多种形式。例如爽肤水、面霜、面膜、防晒霜、晒后修复凝胶、身体乳和保湿喷雾等多种形式，用于体表和面部的皮肤护理。
例如：组合物1-1可以按10份加入量加入常规润肤乳配方中；组合物1-1可以按5份加入量加入常规爽肤水中；组合物1-3可以用纯化水进行3倍稀释配制保湿喷雾；组合物1-4可以按3份加入量加入常规晒后修复凝胶配方中；组合物1-5可以按2份加入量加入常规面霜配方中。
实施例2不同配方抗氧化组合物对紫外辐射诱发自由基的抑制作用
选用平均分子量360kDa、赖氨酸含量16.2%的透明质酸赖氨酸，按下表配制不同比例的样品。
表3不同比例配方主要成分和含量(mg/ml)
抑制紫外辐射诱发自由基的试验
按文献方法[孙赫,王丽丽,康传利等。麦角硫因抑制紫外辐射诱发自由基的试验研究，食品与药品，2023年第6期]测定：以pH 7.2的磷酸盐缓冲液（PBS，取2.2 g Na2HPO4，0.3 g NaH2PO4和8.5 g NaCl，加水溶解至1000 ml）为溶剂，将上述样品稀释1000倍作为供试液，加入罗丹明B溶液（RhB）至浓度为0.001 %。置紫外光（波长254 nm，光强度5 mW/cm2）下照射。分别于0h和1 h时，采用酶标仪，测定555 nm波长处吸收值（A 0和A 1），每个样品平行3份，计算0 h和1 h吸光度变化量的平均值（ΔA），以ΔA 空白为基线，按下式计算供试品的抗氧化性能（F）。
式中，ΔA 空白：空白对照溶液的吸收值的变化量（A 0空白- A 1空白）；ΔA 样品：样品溶液的吸收值的变化量（A 0样品-A 1样品）。
并计算体系中活性物质的抗氧化性能（F值），结果如下。
表4不同供试品的抗氧化性能
结果显示，麦角硫因的含量降低至1ug/ml，其对紫外辐射诱发自由基的抑制作用（抗氧化性能）仅为1.16%，与透明质酸赖氨酸含量110、138、184ug/ml组合后，可以显著提高后者的F值，例如D组与A组相比，F值提高了20%，表现出明显的协同作用。透明质酸二甲基硅烷醇复合物和泛醇的加入，均可以提高组合物的F值，而少量麦角硫因的加入 ，同样可以显著提高组合物的F值，例如 I组与G组相比，F值提高了12%，表现出明显的协同作用。。。
以上结果表明：本发明技术方案，采用较低的EGT使用量与LHA组合，二者发挥协同作用，可显著提高组合物的抗氧化能力，用于制备抗衰美白功效的化妆品可有效降低产品的原料成本，同时保证产品抗氧化效果。
Claims (9)
1.一种用于皮肤抗氧化的组合物，其特征是包含：
a）透明质酸赖氨酸
和b) 麦角硫因；
其中，透明质酸赖氨酸和麦角硫因按重量比为100 ~ 200:1。
2.权利要求1所述的组合物，其特征是，透明质酸赖氨酸和麦角硫因按重量比为120 ~150:1。
3.权利要求1和2所述的组合物，其特征是，所述透明质酸赖氨酸的平均分子量为7kDa~ 1000kDa。
4.权利要求1和2所述的组合物，其特征是，所述透明质酸赖氨酸的平均分子量为10KDa~600kDa。
5.权利要求1和2所述的组合物，其特征是，所述透明质酸赖氨酸的平均分子量为100kDa ~ 300kDa。
6.权利要求1和2所述的组合物，其特征是，还含有透明质酸二甲基硅烷醇复合物和/或泛醇。
7.权利要求1和6所述的组合物，其特征是，还含有化妆品常用防腐剂。
8.权利要求1、6和7所述的组合物，其特征是，所述组合物以凝胶和/或溶液的形式体现。
9.权利要求1、6和7所述组合物用于制备皮肤护理产品的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311532988.1A CN117462430A (zh) | 2023-11-17 | 2023-11-17 | 抗氧化组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311532988.1A CN117462430A (zh) | 2023-11-17 | 2023-11-17 | 抗氧化组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117462430A true CN117462430A (zh) | 2024-01-30 |
Family
ID=89637787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311532988.1A Pending CN117462430A (zh) | 2023-11-17 | 2023-11-17 | 抗氧化组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117462430A (zh) |
-
2023
- 2023-11-17 CN CN202311532988.1A patent/CN117462430A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101060634B1 (ko) | 인산화당을 함유한 피부외용제 | |
| KR101480700B1 (ko) | 복방 생약 추출물을 유효성분으로 함유하는 피부 외용제조성물 | |
| CN109303727B (zh) | 一种含植物提取物的复合抗衰老组合物及其应用 | |
| JP2008201773A (ja) | 皮膚外用剤 | |
| CN109998937B (zh) | 含有甘油葡糖苷(αGG)的系列化妆品及其制备方法 | |
| KR20210041251A (ko) | 흑생강 추출물 및 기능성 식물 추출물을 포함하는 두피용 화장료 조성물 | |
| KR102233140B1 (ko) | 저분자 히알루론산을 함유하는 피부 개선용 화장료 조성물 | |
| CN113730321A (zh) | 一种抗皱紧致组合物及其在化妆品中的应用 | |
| KR101587077B1 (ko) | 피부 생리활성을 가지는 백년초 발효물을 포함하는 조성물 | |
| CN115607476A (zh) | 一种具有保湿抗氧化功效的组合物及其应用 | |
| CN117462430A (zh) | 抗氧化组合物及其应用 | |
| KR102310366B1 (ko) | 시아니딘글루코사이드 및 낫토검을 유효성분으로 함유하는 항노화용 피부 외용제 조성물 | |
| RU2491913C1 (ru) | Косметическая композиция для изготовления средств по уходу за волосами | |
| KR101363029B1 (ko) | 우뭇가사리, 미역, 밀싹 및 베르가못 혼합 추출물을 함유하는 항산화 효과 및 피부 노화 예방 효과를 갖는 있는 화장용 조성물 | |
| KR101145814B1 (ko) | 주름 개선용 조성물 | |
| EP3366273A1 (en) | Moisturizer and cosmetic containing same | |
| EP1009378A1 (fr) | Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
| CN113116765B (zh) | 精华原液及其制备方法和胶原酶抑制剂 | |
| KR20100033729A (ko) | Ｎ-아세틸글루코사민과 비타민 ｃ를 함유하는 화장료 조성물 | |
| KR102050328B1 (ko) | 버섯다당체 함유 천연 유래 복합물을 유효 성분으로 포함하는 산화적 스트레스 억제 활성 보유 화장료 조성물 | |
| KR20160066733A (ko) | (2S)-1-O-리놀레노일-3-O-β-D-갈락토피라노실-sn-글리세롤을 함유하는 보습용 조성물 | |
| KR102215170B1 (ko) | 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 보습용 조성물 | |
| KR20160081161A (ko) | 컴파운드 k 및 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 피부 보습 또는 미백용 외용제 조성물 | |
| KR20160067428A (ko) | (2S)-1-O-리놀레노일-2-O-리놀레노일-3-O-β-D-갈락토피라노실-sn-글리세롤을 함유하는 보습용 조성물 | |
| KR20160082115A (ko) | 컴파운드 K 및 (2S)-1-O-리놀레노일-3-O-β-D-갈락토피라노실-sn-글리세롤을 함유하는 피부 보습 또는 미백용 외용제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |